Trial
NCT05023655
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Prisma Health-Upstate
Collaborators
Ipsen
Condition
Solid Tumor
Intervention
Tazemetostat
Why stopped
Ipsen has discontinued all active tazemetostat clinical trials and expanded access programs due to the emergence of a clinically unfavorable benefit risk profile for tazemetostat in combination with lenalidomide and rituximab.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-17